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Abstract
Matrix metalloproteinases (MMPs) are principal participants in tumor development. In addition to serve as a
useful biochemical marker, MMP expression may also provide a target for the diagnostic in vivo imaging of
tumors, using a radiolabeled inhibitor. This study investigates the use of membrane type 1 (MT1)-MMP as target
for in vivo tumor diagnosis. Specific binding of the endogenous tissue inhibitor of metalloproteinase-2 (TIMP-2)
to MT1-MMP has been previously described. In this study, biodistribution and imaging experiments were
performed on MT1-MMP–overexpressing (S.1.5) and control (C.IV.3) tumor-inoculated mice using [123I]-
recombinant human TIMP-2 (rhTIMP-2) as radioligand and [123I]-rhTIMP-1 as control. The expression profile
was controlled in vitro and on tumor extracts. rhTIMP-2 as well as rhTIMP-1 were labeled using the Iodogen
method and characterized. Biodistribution of [123I]-rhTIMP-2 showed a tumor uptake of 2.87% 1.58% ID/g at 3
hours postinjection in S.1.5. Tumor values of [123I]-rhTIMP-1 and [123I]-rhTIMP-2 evaluated in S.1.5 and C.IV.3,
respectively, were significantly lower. Planar imaging revealed significant uptake of [123I]-rhTIMP-2 in S.1.5
compared with contralateral background areas. This could not be observed in C.IV.3 and with [123I]-rhTIMP-1 in
S.1.5. All tumors were well established (200–800mg). These results suggest that rhTIMP-2 holds potential for
development of radiotracers for in vivo imaging in overexpressing MT1-MMP but not in similar tumors that do
not express this protease.
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Introduction
Cells in tissue degrade and reconstitute the extracellularmatrix at the periphery to carry out various cell func-
tions. Extracellular matrix turnover is an integral part of
normal and pathological processes, such as development,
tissue remodeling, cell growth and differentiation, and inva-
sion and metastasis.1,2 Matrix metalloproteinases (MMPs) are
the principal participants of matrix turnover3 and are divided
into six subgroups: collagenases, gelatinases, stromelysins,
matrilysins, zinc- and calcium-dependent endopeptidases,
and membrane type-MMPs (MT-MMPs).4 Many of these en-
zymes are believed to play a key role in tissue remodeling
associatedwith tumor cell invasion, metastatic dissemination,
and angiogenesis.1,5,6 Because of the direct relationship be-
tween MMP overproduction and tumor progression and
prognosis, MMPs have been a major cancer drug target dur-
ing the past decades, resulting in the development of a wide
variety of metalloproteinase inhibitors (MMPIs).7 Moreover,
their overproduction by tumor tissue when compared with
normal tissues also made them an attractive target for in vivo
imaging.2,5,6 Several attempts with radiolabeled MMPIs to
detect tumor cells in vivo, however, have proven unsuccess-
ful.7–9 Whether or not this relates to shortcomings of the used
imaging probes or to the setup of the reported studies is
currently unclear.9 In addition to custom-made MMPIs, there
have been limited attempts to use the specificity of tissue in-
hibitors of MMPs (TIMPs) to probe for the presence of active
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MMPs in tissues. TIMPs (TIMP 1–4) represent a family of
natural secreted and soluble glycoproteins that inhibit MMP
activity by formation of noncovalent binding with their cat-
alytic binding site with high affinity (Kd¼ 1010 – 1016
M).4,10,11 In a small pilot study, 111In-DTPA-N-TIMP-2 was
injected in 5 patients with Kaposi’s sarcoma; no uptake in the
malignancy could be observed.12 However, Kaposi’s sarcoma
patients secrete MMP-2 and MMP-9, whereas the available
data do not support the hypothesis that 111In-N-TIMP-2 spe-
cifically binds these proteases.7 Given the well-documented
high-affinity interaction betweenMT1-MMP and TIMP-2, this
membrane-bound enzyme might be a more suitable candi-
date for imaging with TIMP-2.7,9 MT1-MMP is of particular
interest because it is essential for angiogenesis and tumor
development in vitro as well as in vivo.13–15 As abundant
presence of MT1-MMPs correlates with the degree of malig-
nancy andmetastasis in various tumor types, it is an attractive
target for in vivo evaluation of tumor aggressiveness.14,15
Accordingly, this study reports on the potential usefulness of
[123I]-TIMP-2 for molecular imaging of MT1-MMP expression
in an in vivo tumor model.
Materials and Methods
Recombinant human TIMP-2 and recombinant
human TIMP-1
Production and purification of recombinant human TIMP-2
(rhTIMP-2), 21kDa, was conducted as previously described.16
rhTIMP-1, 29kDa, was a kind gift from Prof. G. Murphy
from the Department of Oncology, Cambridge University,
Cambridge Institute for Medical Research. rhTIMP-1 served
as negative control.
Cell culture
Two stable transfected A2058 melanoma clones were
used: one transfected with the pcDNA3 (control plasmid)
vector alone (clone C.IV.3) and one with the human MT1-
MMP expression vector (pc3MT1800S) (clone S.1.5). Stable
transfectants were maintained in supplemented Dulbecco’s
modified Eagle’s medium containing G418 (500 mg/mL)
(Invitrogen) as previously described.17 All culture reagents
were purchased from Lonza.
Immunocytochemical staining
MT1-MMP expression in the S.I.5 clone or control C.IV.3
clone was confirmed via indirect immunocytochemical
staining of cells cultured as monolayers in four-well tissue
culture chamber slides (Nunc Lab-Tek). Staining was
conducted using a Dako LSAB2 kit (Invitrogen) as described
earlier.18 Primary anti-active MT1-MMP was purchased from
R&D. Individual green, red, and blue transmission images
were collected using a Spot Insight B/W camera (model
3.1.0) in combination with a CRI Micro Color filter (model
RGB-ELE) using spot software 3.5.9 for Windows. The in-
dividual color transmission images were merged in an RGB
image using imageJ software.19
Western blotting analysis of MT1-MMP in tumor tissue
In vivo expression of MT1-MMP was determined using
Western blotting performed as previously described.17,18
Briefly, samples of total cell extracts were resolved by sodium
dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing conditions and proteins were trans-
ferred to polyvinylidine difluoridemembranes (PVDF transfer
membrane; Perkin Elmer). The membranes were exposed to
primary antibodies (1/50,000) raised against the hemopexin
domain of MT1-MMP (ascites liquid 3H3), kindly provided by
M-C Rio (IGBMC), followed by a horseradish peroxidase-
conjugated goat anti-mouse antibody (1/1000; Dako). Protein
bands were visualized using an enhanced chemiluminescence
kit (NEN), according to the manufacturer’s instructions.
Enzyme-linked immunosorbent assay
TIMP-2 quantification
TIMP-2 concentrations in tumor extracts of C.IV.3 and
S.1.5 were determined using sandwich enzyme-linked im-
munosorbent assays (ELISAs) as previously described.17 The
sensitivity of this ELISA for TIMP-2 was 0.5 ng/mL and
the concentration versus absorbance curve was linear in the
0.5–40 ng/mL range. Each sample was run in duplicate.
Synthesis of [123I]-rhTIMP-2 and [123I]-rhTIMP-1
Radiosynthesis was performed using the Iodogen tech-
nique as described by Haisma et al.20 rhTIMP-2 in Tris buffer
or rhTIMP-1 in 0.1M phosphate-buffered saline (PBS) at pH
7.5 and Na123I (37–740MBq dependent on the experiment)
(Bristol-Meyers Squibb) were added to a Iodogen-coated
vial. After 10 minutes at room temperature, [123I]-rhTIMP-2/
[123I]-rhTIMP-1 were purified on a standard prepacked PD-
10 size exclusion column (Amersham Pharmacia) using a
0.5% BSA (bovine serum albumin solution; Sigma) in PBS
(referred to as PBS/BSA) as an eluting agent.
Characterization of [123I]-rhTIMP-2 and [123I]-rhTIMP-1
Instant thin-layer chromatography (ITLC) (Pall Cor-
poration) eluted with 20mM citric acid was performed to
check radiochemical purity of the pooled fractions. Radi-
olabeled proteins were analyzed by SDS-PAGE, and ra-
dioactivity associated with the protein bands was measured
using ImageQuant software of a Phosphor imaging system
(Cyclone; Perkin Elmer). For determination of the purity of
[123I]-rhTIMP-2 and [123I]-rhTIMP-1 after radiolabeling,
analytic size-exclusion high-performance liquid chroma-
tography was performed using a Shodex KW 802.5 column
(7.8300mm; Thomson Instrument Company). In vitro
stability of [123I]-rhTIMP-1 was assessed as previously de-
scribed for [123I]-rhTIMP-2.21 For affinity determination,
scatchard analysis of [123I]-rhTIMP-2 was performed in
triplicate on adherent S.1.5 and C.IV.3 cells. Nonspecific
binding was determined using 100-fold molar excess of
nonlabeled rhTIMP-2. Nonlinear regression and Kd values
were determined using GraphPad Prism Software 5.0.
In vivo studies
All procedures involving animals were in conformity with
the regulations of the Belgian law and the local Ethical
Committee (ECP02/36, ECP03/30, and ECD07/14).
Blood clearance studies. Pharmacokinetic studies were
conducted by obtaining blood samples (10 mL) via tail bleeds
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at various time points after injection of 740 kBq of each of the
radioiodinated proteins in 6–8-week-old Swiss nu/nu mice
without tumor (n¼ 3). The data were fitted according to a
two-phase exponential decay curve and half-lives were cal-
culated using GraphPad Prism Software.
Biodistribution in S.1.5- and C.IV.3-inoculated mice.
Four-week-old male Swiss nu/nu mice were injected subcu-
taneously in the flank with 5106 C.IV.3 or S.1.5 cells in
serum-free medium, suspended in an equal volume of Ma-
trigel (Becton Dickinson Labware). When the tumor reached
a volume of *1 cm3 (3–4 weeks), the mice (n¼ 3–5) were
used for biodistribution studies. Tumor weight ranged from
120 to 1000mg (565 287mg). To study the in vivo specificity
of tumor uptake, two separate experiments were performed.
In the first, the uptake of [123I]-rhTIMP-2 was compared in a
overexpressing tumor model (S.1.5) and a control tumor with
minor MT1-MMP expression (C.IV.3). In the second experi-
ment, uptake of [123I]-rhTIMP-2 in S.1.5 was compared with
the uptake of [123I]-rhTIMP-1, a comparable endogenous in-
hibitor, not binding MT1-MMP.21 About 0.74MBq (0.5 mg,
200 mL) of [123I]-rhTIMP-2 or [123I]-rhTIMP-1 was intrave-
nously injected in S.1.5- or C.IV.3-inoculated mice. After 1, 3,
6, 9, and 24 hours postinjection (p.i.), the mice were sacrificed
by decapitation under isoflurane anesthesia. Blood was
drawn, and tissue samples were dissected, washed, dried,
weighed, and counted for radioactivity with a Cobra auto-
mated gamma counter (Cobra II Series; Canberra Packard).
The injected dose (ID) was calculated by weighing the sy-
ringes before and after injection of the tracer and by the use
of dilution series of the tracer solution, which was also
weighed and counted for radioactivity. The concentration of
radioactivity was decay corrected and percentage of ID per
gram (% ID/g) was calculated for each organ.
Effect of absolute amount. To study the effect of amount
of tracer, an additional experiment with 5mg [123I]-rhTIMP-2
was performed. Twenty-four (24) hours after injection of
37MBq [123I]-rhTIMP-2 or [123I]-rhTIMP-1, mice bearing S.1.5
of C.IV.3 tumors were sacrificed and radioactivity distribu-
tion in blood, tumor, and organs was measured as described
earlier.
Metabolite analysis and in vivo blood stability. S.1.5-
inoculated mice were injected intravenously (i.v.) with
1.85MBq [123I]-rhTIMP-2 and S.1.5 tumor tissue was excised
3 hours p.i. Tumor tissue was homogenized using a ‘‘potter
grinder’’ and cold extraction buffer (Tris-HCl 0.05M, NaCl
0.1M, Tween 2%). All manipulations were performed on
ice. The suspension was centrifuged and supernatant was
collected. Blood samples, collected in ethylenediaminete-
traacetic acid tubes, were centrifuged for 15 minutes at 6000 g.
Different molecular weight (Mw) fragments in tumor
homogenates and plasma samples were separated by size
exclusion on a PD-10 column. The eluate was collected in
fractions of 0.5mL and counted for radioactivity. To vali-
date the extraction procedure, blood and tumor samples
from noninjected mice (n¼ 3) were spiked with 37 kBq of
the labeled compound, after which the same procedure was
conducted. The extraction yield is expressed as percentage
of total radioactivity recovered in the supernatant. In ad-
dition, a plasma sample was examined by SDS-PAGE on a
15% polyacrylamide gel to determine the origin of Mw
fractions.
Planar gamma imaging. Nu/nu athymic mice bearing
well-established S.1.5 or C.IV.3 tumors (1 cm3) under the
forepaw (n¼ 3–5) were tail-vein injected with 37MBq (5 mg)
123I tracer. All mice received 0.1% NaI in their drinking water
24 hours prior to injection of the tracer to prevent thyroid
uptake of free iodine. During all imaging experiments, the
animals were anesthetized with isoflurane (induction 5%,
maintenance 1%–2% by inhalation) and placed in a prone
position. At 1, 6, and 24 hours p.i., images were acquired
using a Prism 3000XP Single-Photon Emission Computed
Tomography camera equipped with a high-resolution parallel-
hole collimator. All images were acquired into 256256
matrices (FOV: 23.512.46 cm), with a photopeak window
set at 15% around 159 keV, and processed with a HERMES
image process system. Regions of interest were drawn and
mean tumor-to-contralateral background ratios were calcu-
lated for all animals. Image time was corrected for radioac-
tivity decay of [123I] and equal intensity is shown for
comparison. At the end of the experiment, all mice were
sacrificed and dissected.
Statistical analysis
Experimental data of biodistribution and imaging experi-
ments were analyzed with GraphPad Prism software. Data
are expressed as mean standard deviation and statistical
significance of differences between [123I]-rhTIMP-2 and [123I]-
rhTIMP-1 and between uptake in S.1.5 and C.IV.3 tumors
was analyzed by a nonparametric Mann–Whitney U-test. A
p-value of <0.05 was considered significantly different.
Results
Characterization of the used cell lines
Immunocytochemical staining of MT1-MMP on cells cul-
tured in chamber slides showed specific staining of S.1.5 cell
membranes and almost no membrane staining on C.IV.3 cells
(Fig. 1A). As the cells were not permeabilized, only mem-
brane-expressed MT1-MMP was detected. To confirm the
in vivo expression, Western blotting was performed on tumor
tissue. Both 63 and 60 kDa bands, corresponding to pro-MT1-
MMP and an active form of MT1-MMP, respectively, were
detected at higher levels in clone S.1.5. A similar profile of
MT1-MMP was observed in vitro using S.1.5 cells (Fig. 1B). A
larger band of 43 kDa was detected in both S.1.5 tumor and
cell extracts; this is a cell-surface associated inactive form that
results from MMP-dependent processing of the 60 kDa
form.21 In the cell extracts, this band is more abundant, most
probably because of the heterogeneity of the tumor mass,
existing from tumor cells, combined with tumoral fibroblast
and other stroma cells.
Radiolabeling and quality control
The overall radiochemical yield was 68% 13.0% and
66% 7.5% for [123I]-rhTIMP-2 and [123I]-rhTIMP-1, respec-
tively. High specific activities were obtained, ranging from
24 to 240 GBq/mmol. Radiochemical purity of the [123I]
tracers recovered at the end of synthesis was 98% as
determined by ITLC and radio-high-performance liquid
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chromatography. Protein integrity was also demonstrated by
analyzing the radioactivity after SDS-PAGE separation.
Electrophoresis of the radiolabeled proteins showed >99% of
the total radioactivity associated with the protein band of Mr
* 21,000 for rhTIMP-2 (Fig. 1C, lane 1) or Mr * 29,000 for
rhTIMP-1 (Fig. 1C, lane 2). Radiochemical stability of [123I]-
rhTIMP-1 was >90% up to a 24 hours incubation period in
PBS or Dulbecco’s modified Eagle’s growth medium as de-
termined by ITLC analysis. After 24 hours in mouse serum at
378C, a loss of 20% of the radiolabel could be observed. These
results are comparable to those of [123I]-rhTIMP-2, published
earlier.21 Scatchard analysis of [123I]-rhTIMP-2 on adherent
S.1.5 cells was performed resulting in a Kd of 1.18 0.11 nM
and a Bmax of 83.60 fmol/cell. As expected, for C.IV.3 and the
control protein [123I]-rhTIMP-1 no specific binding could be
shown.
Enzyme-linked immunosorbent assay
TIMP-2 is an endogenous inhibitor of all MMPs. The
presence of host TIMP-2 might influence the tumor uptake
by competition. ELISA analysis was performed in duplicate
and revealed a TIMP-2 concentration ranging from 56.8 to
89.6 ng/mL in C.IV.3 tumors and from 115.5 to 154.8 ng/mL
in S.1.5 tumors.
Biodistribution
The diagnostic potential of proteins for in vivo tumor im-
aging depends on their rapid blood clearance and ability to
accumulate in the tumor. To determine the blood clearance
of [123I]-rhTIMP-2 and [123I]-rhTIMP-1, pharmacokinetic
studies were conducted. After injection in nontumor-bearing
nu/numice (n¼ 4–6), both [123I]-rhTIMP-2 and [123I]-rhTIMP-
1 displayed a rapid equilibration phase (T1/2a, 1.92 and 1.32
minutes, respectively) and subsequent slower elimination
phase (T1/2b, 143 and 112.6 minutes) from the circulation.
Both constructs have approximately the same size, 21 and
29 kDa, and show similar fast excretion from the body.
To evaluate the MT1-MMP tumor-targeting potential of
[123I]-rhTIMP-2, studies were performed in nu/nu mice bear-
ing subcutaneous S.1.5 or C.IV.3 control tumors (n¼ 3–6),
using 0.5mg of purified radioiodinated rhTIMP-2 or rhTIMP-1.
The results of the distribution of radioactivity of [123I]-TIMP-2
in the tissues of S.1.5-bearing mice are summarized in
Figure 2A. A higher blood concentration can be observed at
all time points compared with the pharmacokinetic studies
in tumor-free nu/nu mice. Among normal tissues, kidneys
showed the highest concentration of [123I] activity, indicating
renal elimination of the small protein (<30 kDa). Kidney
uptake was highest with 25.3% 2.9% ID/g at 1 hour p.i.
and decreased to 1.87% 0.2% ID/g at 24 hours p.i. Deha-
logenation was indicated by uptake in the stomach of 16.3%
ID/g at 1 hour p.i. The maximum activity measured in the
tumor was 2.9% 1.6% ID/g at 3 hours, with a corre-
sponding tumor-to-blood ratio of 0.41 and a tumor-to-muscle
of 3.21, after which a slow decrease of 0.2% 0.1% ID/g
24 hours p.i. was seen (Fig. 2C). In the S.1.5 tumor-inoculated
mice, radioactivity concentration decreased slower in the
tumor than in the blood, reflecting specific binding to tumor
tissue. The high blood concentration of [123I]-rhTIMP-2
in S.1.5-inoculated mice, however, resulted in rather low
tumor-to-blood ratios.
A control cell line, C.IV.3, with minor expression of MT1-
MMP, and a control protein, rhTIMP-1, were included to
study the specific in vivo targeting of MT1-MMP (n¼ 3). As
the tumor has a different MT1-MMP expression pattern, re-
FIG. 1. Analysis of MT1-MMP expression in a A2058 clone transfected with control vector (C.IV.3) and a clone transfected
with MT1-MMP cDNA (S.1.5). (A) Immunocytochemical staining of MT1-MMP on S.1.5 (1þ) and C.IV.3 (2þ) cells cultured in
chamber slides. Controls are without primary anti-MT1-MMP antibody (1 and 2, respectively). Magnification: 1040. (B)
Western blot analysis of S.1.5 (lane 1) and C.IV.3 (lane 2) tumor extracts. S.1.5 cell extract included as control (lane 3). The
63 kDa band corresponds to pro-MT1-MMP, the 60 kDa to the active form of MT1-MMP, and the 43 kDa band to the
autocatalytically cleaved form. (C) Phosphorescence image of [123I]-TIMP-2 (lane 1) and [123I]-TIMP-1 (lane 2) separated by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis analysis on a 15% polyacrylamide gel. MT1-MMP, membrane
type 1-matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteinase.
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duced uptake of [123I]-rhTIMP-2 was expected. As seen in
Figure 2B, [123I]-rhTIMP-2 accumulated only marginally in
the C.IV.3 tumors, without retention. After 3 and 6 hours p.i.,
the total activity was 1.1% 0.7% and 0.5 0.2% ID/g,
respectively, which is significantly lower than in S.1.5 xe-
nografts ( p< 0.05; Fig. 2B, C). But the radioactivity uptake
of all well-perfused organs in C.IV.3-inoculated mice was
also significantly lower compared with S.1.5-inoculated
mice, reflecting the lower blood concentrations than in S.1.5-
inoculated mice.
[123I]-rhTIMP-1 was injected in 4 S.1.5 tumor-bearing mice
per time point and comparable blood and organ values were
seen with [123I]-rhTIMP-2. At 1 hour p.i., no difference was
observed in tumor tissue, probably reflecting the tracer
concentration in the blood flow of the highly vascularized
S.1.5 tumors. But significantly lower absolute tumor values
( p< 0.05) were measured in the control experiment at 3 and
6 hours p.i., with a minimal and declining tumor uptake (Fig.
2C). This further supports a MT1-MMP–dependent [123I]-
rhTIMP-2 retention in the tumors.
To investigate the origin of higher [123I]-rhTIMP-2
concentrations in the blood of MT1-MMP–overexpressing
tumor-bearing animals (S.1.5), blood concentrations of [123I]-
rhTIMP-2 in tumor-free Swiss nu/nu mice (n¼ 3) were com-
pared with those in tumor-inoculated mice. Not only blood
values were significantly lower in tumor-freemice ( p< 0.05 at
3, 6, and 24 hours p.i.), but also they were lower in C.IV.3-
inoculated mice ( p< 0.05 at 1, 3, and 6 hours p.i.). The blood
values of control protein ([123I]-rhTIMP-1), on the other hand,
were comparable to those of [123I]-rhTIMP-2 in S.1.5 (Fig. 2D).
FIG. 2. Comparison of [123I]-TIMP-2 distribution in S.1.5- (A) and C.IV.3- (B) inoculated nu/nu mice, at 1, 3, 6, and 24 hours
p.i. (*p< 0.05, [123I]-TIMP-2 in S.1.5 vs. in C.IV.3) (n¼ 4–6). (C, D) Plots of tumor and blood levels of [123I]-TIMP-2 and [123I]-
TIMP-1 in S.1.5- and C.IV.3-inoculated mice and in nu/nu mice without tumor versus time p.i. (n¼ 3–6). (C) Tumor clearance
study (*p< 0.05 at 3 and 6 hours p.i. for [123I]-TIMP-2 in S.1.5 and C.IV.3 and for [123I]-TIMP-2 and control protein [123I]-
TIMP-1 in S.1.5). No difference was observed between two controls. (D) Comparison of blood levels indicates the higher
blood concentration of [123I]-TIMP-2 and [123I]-TIMP-1 in S.1.5. Nonlinear two-phase decay fit (GraphPad Prism 5) was used.
Significant differences (*p< 0.05) calculated between [123I]-TIMP-2 in S.1.5-inoculated mice and nu numice (3, 6, and 24 hours
p.i.)/C.IV.3-inoculated (1, 3, and 6 hours p.i.) mice. No difference of [123I]-TIMP-1 and [123I]-TIMP-2 in S.1.5. The mean
percentage of injected dose per gram of tissue is plotted, with error bars indicating standard deviations. p-Values are based on
Mann–Whitney U-test. p.i., postinjection.
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Figure 3 compares the influence of total amount of
protein injected on the biodistribution of [123I]-rhTIMP-2 in
S.1.5-inoculated mice. A 10-fold higher amount (5mg) has
been injected and mice (n¼ 6) were sacrificed at 24 hours p.i.
Blood, liver, kidneys, and lungs showed significantly lower
% ID/g uptake using 5mg [123I]-rhTIMP-2 compared with
0.5 mg ( p< 0.01), whereas the uptake of radioactivity in
less-perfused organs was analog (Fig. 3A). Lower blood
values (0.10% 0.02% ID/g) and higher tumor uptake
(0.14% 0.03% ID/g) consequently resulted in a higher
tumor-to-blood value of 0.98 0.02 (Fig. 3B). Given the three
times higher tumor-to-blood ratio of 5 mg [123I]-rhTIMP-2 in
S.1.5, control experiments were repeated with 5 mg protein.
As anticipated, [123I]-rhTIMP-1 showed negligible tumor
uptake of 0.08% 0.02% and 0.05% 0.02% ID/g in S.1.5
and C.IV.3, respectively. Data of [123I]-rhTIMP-2 in C.IV.3
(0.03% 0.02% ID/g) were comparable, accounting for the
wash-out of the protein. As both blood and tumor showed
no retention of the inhibitor, tumor-to-blood ratios are not
significantly different among controls ( p< 0.05) and are
lower than [123I]-rhTIMP-2 in S.1.5 (Fig. 3C).
Planar gamma imaging
Planar imaging of both [123I]-rhTIMP-2 and [123I]-rhTIMP-
1 was performed in S.1.5 and C.IV.3. Figure 4 shows the
images of tumor-bearing mice at different time intervals after
injection. The S.1.5 tumor was clearly depicted using [123I]-
rhTIMP-2. High uptake can be observed in stomach, bladder,
and kidneys. Regions of interest were drawn and tumor-to-
contralateral background ratios were calculated (n¼ 4–10)
(Table 1). Significant differences at all time points between
[123I]-rhTIMP-2 and [123I]-rhTIMP-1 in S.1.5 and [123I]-
rhTIMP-2 in S.1.5 and C.IV.3 can be observed ( p< 0.05). No
significant differences were noticed among controls. This is
consistent with Western blot results of tumors showing a
higher MT1-MMP expression in S.1.5 tumors.
In vivo stability and metabolization
From the blood clearance studies, biodistribution, and
imaging experiments, only the quantitative presence of ra-
dioactivity in the blood and organs can be determined. In-
formation on the integrity of the proteins cannot be obtained
by these experiments. To identify the compound located in
blood and tumor tissue, metabolization studies in the S.1.5-
inoculated mice (n¼ 4) were performed. The tracer was
extracted from tumor tissue at 3 hours after injection of [123I]-
TIMP-2, and plasma was separated by centrifugation. Spiked
plasma and tumor samples did not show protein degrada-
tion. Blood samples as well as tumor extracts were separated
using SEC on PD10 and resulted in two distinct peaks of
radioactivity encompassing fractions 7–10 (high Mw com-
pound) and 16–24 (low Mw compound). Figure 5A demon-
strates that 54% 1.8% of high Mw and 40.9% 1.9% of low
Mw compound were detected in the blood at 3 hours p.i. In
FIG. 3. (A) The influence of amount of protein by in vivo comparison of 0.5 and 5mg of [123I]-TIMP-2 in S.1.5. (B) Lower
blood values combined with comparable tumor uptake leads to significantly higher tumor-to-blood ratios. (C) The influence
of 5mg [123I]-TIMP-2 and [123I]-TIMP-1 in S.1.5 and C.IV.3 on tumor-to-blood (controls). All data represent mean standard
deviation (n: 3–6) at 24 hours p.i. (White) 0.5 mg [123I]-TIMP-2 in S.1.5; (black) 5 mg [123I]-TIMP-2 in S.1.5; (gray) 5mg [123I]-
TIMP-2 in C.IV.3; (vertical) 5mg [123I]-TIMP-1 in S.1.5; (diagonal) 5 mg [123I]-TIMP-1 in C.IV.3. **p< 0.01 and *p< 0.05, based
on Mann–Whitney U-test.
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the tumor, 89.1% 0.3% of the activity was represented by a
low Mw compound. To identify the high-Mw degradation
product, samples of plasma, free iodine, and pure [123I]-
TIMP-2 were analyzed by SDS-PAGE. On a 15% polyacrylamide
gel (Fig. 5B), three clear bands were detected in the plasma:
one of 21 kDa, corresponding to the intact tracer, one
of 100 kDa, and free [123I]. The larger band could be at-
tributed to a 123I-protein coupled to shed MT1-MMP, MMP-
2, other MMPs, or 123I-protein complexed to serum proteins.
Discussion
The present study demonstrates that rhTIMP-2 and
rhTIMP-1 can be successfully iodinated with high specific
activity and excellent in vitro stability. Further, the potential
use of [123I]-rhTIMP-2 for in vivo imaging in a mouse tumor
model overexpressing MT1-MMP is described. Iodination
was chosen over 111In-DTPA conjugation construction in
these scouting experiments, because of the possible hetero-
geneity of the DTPA-conjugate.8
Overexpression or absence of the targeted proteinase in vitro
as well as in vivo was documented in two A2058 clones that
overexpressed MT1-MMP (S1.5 clone) or not (C.IV.3).17 Re-
verse transcriptase (RT)–polymerase chain reaction, Northern
blotting, immunocytochemistry, Western blotting, and flow
cytometry (data not shown) demonstrated high levels of MT1-
MMP transcripts and protein only in S1.5 tumors and cells that
had been generated by transfection with MT1-MMP cDNA.
On the contrary, the control clone C.IV.3, transfected with an
empty vector, exhibited only minimal amounts of MT1-MMP.
TIMP-1 was used as control, as it shows a comparable binding
as TIMP-2 to all soluble MMPs but is unable to bind MT1-
MMP.22
The present study demonstrates the expected specific
binding capacity of [123I]-rhTIMP-2 on S.1.5 cells, resulting
in a Kd of 1.18 0.12 nM, but not of [123I]-rhTIMP-1. These
results were comparable to binding assays performed on
clone S.1.11, another MT1-MMP–overexpressing A2058 clone
(A. Noe¨l, personal communication, unpublished data), on
MT1-MMP–transfected COS-1 cells (1.39 nM)23 and HT1080
fibrosarcoma tumor cells (2.54 nM).24,25 Interactions between
MT1-MMP and TIMP-2 have been previously well charac-
terized. It is widely accepted that binding of TIMP-2 with
MT1-MMP occurs primarily through N-terminal domain
interactions, thereby forming a secondary complex receptor
for pro-MMP-2 activation.26,27 Studies to displaceMT1-MMP–
bound TIMP-2 in a purified system with active MMP-2
showed minimal displacement of inhibitor, under the exper-
imental conditions, because of the high-affinity interaction
between TIMP-2 andMT1-MMP.27 There is also evidence that
[125I]-rhTIMP-2 internalizes and that this reflects the inter-
nalization of MT1-MMP.17,28–30
One of the major advantages of small antibody fragments
and small proteins, such as TIMPs, for in vivo imaging, is
their rapid blood clearance. Pharmacokinetic studies per-
formed in tumor-free nu/nu and nmri mice showed a similar
clearance rate for [123I]-rhTIMP-2 and [123I]-rhTIMP-1. Bio-
distribution studies in S.1.5-inoculated mice, however,
demonstrated significantly higher blood concentrations for
both [123I]-rhTIMP-2 and [123I]-rhTIMP-1 at early time points
and a consequently higher overall organ uptake when
compared with C.IV.3-inoculated mice, tumor-free nu/nu
FIG. 4. Detection of MT1-MMP overexpression in S.1.5
tumors with 5 mg [123I]-TIMP-2 and control experiments.
Planar gamma imaging of anesthetized (1%–2% isoflurane)
nu/numice bearing S.1.5 (A, C) and C.IV.3 (B, D) tumors was
performed at 1, 6, and 24 hours after injection of 37MBq
[123I]-TIMP-2 (A, B) or [123I]-TIMP-1 (C, D). Image time was
corrected for radioactive decay of [123I] and equal intensity is
shown for comparison. Images represent an example of 3–6
mice examined. Tumors were inoculated under the forepaw
and are indicated by ‘‘t’’; stomach (s); bladder (b); kidney (k);
thyroid (th).
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mice, or nmri mice.31 The underlying cause for the observed
higher blood activity is currently unclear. A possible expla-
nation is that soluble forms of MT1-MMP, present in the
plasma, arise from cell surface shedding32 and may signifi-
cantly bind TIMP-2, accounting for the high [123I]-rhTIMP-2.
However, this cannot explain the high concentration of
[123I]-rhTIMP-1 present in the plasma of S.1.5-inoculated
mice, because TIMP-1 cannot bind the catalytic domain of
MT1-MMP.22 An alternative (and not mutually exclusive)
explanation is that S.1.5 cells result in the accumulation of
other active MMPs in the plasma, such as activated MMP-2,
as previously documented.18 This could account for the in-
creased levels of both [123I]-rhTIMP-1 and 2 because both
bind to activated MMP-2 in a stoichiometric 1:1 ratio.33 In the
series presented, high-Mw complexes were identified in
plasma in the metabolization studies. Hypothetically, these
high-Mw complexes may be attributed to [123I]-TIMP-2/
MMP-complexes. Further investigations to clarify this issue
are warranted.
Because of the high retention of [123I]-rhTIMP-2 in the
blood of S.1.5-inoculated mice, calculated tumor-to-blood
ratios were situated more or less in the same range as for the
control (C.IV.3) tumors. However, when considering the
radioactivity concentrations for both proteins in both tu-
mors, it is clear that higher uptake of [123I]-rhTIMP-2 in
S.1.5 cannot solely be assigned to higher blood concentra-
tions of the tracer, given the lower tumor uptake of [123I]-
rhTIMP-1. Importantly, when compared with Western blot
results, absolute tumor uptake in S.1.5 was not as high as
expected from earlier in vitro experiments. In this regard,
ELISAs have shown a TIMP-2 concentration of 56.8–89.6
and 115.5–154.8 ng/mL in C.IV.3 and S.1.5 tumor extracts,
respectively. Thus, the higher endogenous TIMP-2 expres-
sion in S.1.5 might have affected tumor uptake by a com-
Table 1. Tumor-to-Background Ratio of [123I]-Tissue Inhibitor of Metalloproteinase-2 or [123I]-Tissue
Inhibitor of Metalloproteinase-1 in S.1.5 or C.IV.3 Tumor-Bearing Mice at 1, 6, and 24 Hours Postinjection
S.1.5 C.IV.3
1 hour 6 hours 24 hours 1 hour 6 hours 24 hours
[123I]-TIMP-2 3.65 1.32a 4.47 1.14a 8.95 1.66a 1.34 0.29 1.23 0.33 1.08 0.23
[123I]-TIMP-1 2.07 0.86 2.23 0.95 2.20 0.82 1.63 0.76 2.13 0.31 1.74 0.36
Tumor-to-contralateral background ratio values represent the mean standard deviation of data from three measurements per animal and
3–5 animals per experiment.
aValues of [123I]-TIMP-2 in S.1.5 images were compared with all controls separately for significance level. All controls were not significantly
different among each other. p< 0.05; Mann–Whitney U-test.
TIMP-2, tissue inhibitor of metalloproteinase-2.
FIG. 5. Metabolization profile of [123I]-TIMP-2 in S.1.5-inoculated mice at 3 and 24 hours p.i. (A) Pd10 size-exclusion
fractioning of plasma and tumor extract at 3 hours p.i. and the radioactivity of the fractions plotted as percentage of the total
loaded radioactivity. Data are represented as mean standard deviation of 3 mice. (B) Sodium dodecyl sulfate–polyacryl-
amide gel electrophoresis on a 15% gel followed by autoradiography of (lane 1) [123I]-TIMP-2 after 3 hours at 48C; (lane 2)
plasma of a S.1.5-inoculated mouse at 3 hours p.i. of [123I]-TIMP-2; and (lane 3) free 123I.
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petitive effect. Both the endogenous TIMP-2 competitive
effect and the higher tracer presence in the blood com-
partment should be, at least partially, overcome by in-
creasing the injected protein amount and augmenting
specific activity. Thus, instead of 0.5 mg protein, *5 mg
[123I]-rhTIMP-2 was administered to S.1.5- and C.IV.3-
inoculated mice. At 24 hours p.i., significantly higher
tumor-to-blood ratios for 5 mg tracer in S.1.5 were calcu-
lated. Increasing the amount of protein injected has a direct
influence on blood concentration, because all well-perfused
organs have significant lower uptake of the radioactive
tracer, whereas in other tissues, such as tumor and muscle,
no difference can be observed. As anticipated, the decrease
of blood radioactivity favorably modified tumor-to-blood
values for [123I]-rhTIMP-2 in S.1.5-inoculated mice when
compared with controls.
These higher T/B values resulted in a distinct S.1.5 tumor
visualization with [123I]-rhTIMP-2 by planar gamma imag-
ing. No tumor localization in the control groups was evident,
with the images only showing blood pool activity. Uptake in
stomach, bladder, and kidney region was comparable for all
groups and most likely due to dehalogenation and kidney
clearance. Higher blood saturation of [123I]-rhTIMP-1 in
S.1.5-inoculated tumors is clearly not sufficient for delinea-
tion of the tumor. This finding further proves that defined
localization of the tumor in S.1.5-inoculated mice is attrib-
utable to specific targeting of [123I]-rhTIMP-2 to MT1-MMP.
As previously described, the TIMP-2/MT1-MMP complex is
internalized and TIMP-2 is degraded in intracellular organ-
elles. Because of this internalization and subsequent re-
cycling of MT1-MMP, [123I]-rhTIMP-2 could be metabolized
intracellular, resulting in low-molecular-mass degradation
fragments.17 The presence of*90% of low-Mw compound in
tumor extracts in the metabolization studies indicates that
internalized protein is indeed degraded in the tumor, how-
ever, without affecting tumor imaging.
Experiments with MMPIs or with a MT1-MMP blocking
antibody could be performed in the future to give a clearer
view on specificity of [123I]-rhTIMP-2 uptake at the tumor
site and the origin of blood retention. It is also important to
notice that in vivo, not only tumor cells but also mainly
surrounding stroma cells and tumorigenic endothelial cells
express MT1-MMP.13 Therefore, it would be interesting to
evaluate tumors expressing lower levels of MT1-MMP to
study the influence of induced overexpression on blood
uptake of the tracer. In addition, other tumor models with
less-explosive growth than S.1.5 will probably give rise to
smaller malignancies with less-necrotic and -hypoxic areas,
which could influence tracer uptake.
Conclusions
In conclusion, [123I]-rhTIMP-2 is a radioligand that binds
both in vitro and in vivo to MT1-MMP–expressing tumor
cells. Despite the high variation in blood concentrations,
possibly caused by cell shedding or release of active MMP-2,
and the dehalogenation (reflected by high stomach uptake)
of [123I]-rhTIMP-2 in vivo, this study shows the potential of
MT1-MMP imaging as tumor marker. The development of
more stable radioligands with high affinity for MT1-MMP,
such as monoclonal antibodies and antibody constructs,
could overcome the problems associated with [123I]-rhTIMP-
2. In the future, molecular imaging of this protease could be
useful for in vivo evaluation of specific MT1-MMP–inhibiting
strategies.
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